CG:688185 Cansino Biologics Inc A

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides; and DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. It also develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; TB Booster for the BCG-vaccinated population; and Ad5-nCov, a recombinant novel coronavirus disease vaccine. In addition, the company is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB105 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. It has a collaboration with The National Research Council of Canada to advance vaccine against COVID-19; and co-development agreement with Precision NanoSystems, Inc. to develop a mRNA lipid nanoparticle vaccine against COVID-19. CanSino Biologics Inc. was founded in 2009 and is headquartered in Tianjin, the People's Republic of China.

257.90 CNY
As of 01/25/2022


Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  China
Country of incorporation:  China
IPO date:  08/13/2020
Stock exchange:    Shanghai Stock Exchange
Exchange country:   China
Market cap:   44,968,472,576 CNY
Current dividend yield:   0.00%
Sedol:      BMD9JD3

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy